drugset / Trial / NCT01263093

A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel

NCT01263093

Phase 1 Completed 47 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to measure how much of the study drugs (clopidogrel and LY2216684) reach the blood stream and how long it takes the body to dispose of them and to determine how clopidogrel and LY2216684 might affect each other in the body. Information about any side effects that may occur will also be collected.

Timeline

Start
2010-12
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Clopidogrel Small molecule 300 mg Oral
Subject edivoxetine Small molecule 18 mg Oral